Ask AI
ProCE Banner Activity

Conference to Clinic—Advancing Integration of BTK Inhibitors in CLL/SLL Treatment: Expert Insights on Evolving Approaches to Optimize Care

Slideset

These downloadable slides highlight expert perspectives on optimizing the use of BTK inhibitors in the treatment of CLL/SLL. Here, experts review key clinical data, evolving treatment strategies, and evidence-based recommendations for therapy selection, sequencing, and management of adverse events to improve patient outcomes.

Released: October 22, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Faculty Disclosure

Primary Author

Sameh Gaballa, MD: consultant/advisor/speaker: AbbVie, Adaptive Biotechnologies, ADC Therapeutics, AstraZeneca, BeOne, Incyte, Ipsen, Lilly, Regeneron.

Nitin Jain, MD: advisor/honoraria: AbbVie, Adaptive, AstraZeneca, Autolus, BeOne, Bristol Myers Squibb, Cellectis, Genentech, Janssen, Kite/Gilead, Lilly, Novalgen, Nurix, Pharmacyclics, SERB Pharma; research: AbbVie, Adaptive, ADC Therapeutics, Ascentage, AstraZeneca, BeOne, Bioheng, Bristol Myers Squibb, Carna, Cellectis, Fate, Genentech, Kisoji, Kite/Gilead, Lilly, Mingsight, Newave, Novartis, Precision Biosciences, Pharmacyclics, Sana, Takeda, Triarm, Ubix.